SHANGHAI, CHINA--(Marketwire - October 09, 2007) - Sinobiomed Inc. (“Sinobiomed”, or “the Company”) (OTCBB: SOBM) is pleased to announce that Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. (“Shanghai Wanxing”), the Company’s 82% owned subsidiary, has been granted a patent by the State Intellectual Property Office of the People’s Republic of China (PRC) for “recombinant hepato regeneration factor”.
